



To: Head Dept of Rheumatology  
Drug and Therapeutics Committees  
Cc: Consultant rheumatologists

## Invitation to the Novartis symposium on Advances in the treatment of psoriatic arthritis

Treatment according to treat-to-target has become an increasingly established approach in the treatment of chronic arthritides. When treating psoriatic arthritis, it is important to consider that the disease may affect both joints and skin, but can also give rise to enthesitis, dactylitis, axial disease, and nail psoriasis, where these disease manifestations show varying responses to different types of anti-rheumatic treatment.

The recently updated GRAPPA treatment guidelines focus on the different manifestations of the disease as well as associated co-morbidities and their different responses to anti-rheumatic medication, in order to facilitate the treatment of psoriatic arthritis according to the treat-to-target principle. As the number of treatment options have increased over the last years, different treatment guidelines have been updated, taking into account both new evidence as well as various co-morbidities which may influence the choice of treatment.

Novartis is happy to invite to a lecture with Professor in Rheumatology, Glenn Haugeberg, Trondheim University, Norway, who will give a lecture on Advances in the treatment of psoriatic arthritis. The lecture will be moderated by Sr Professor in Rheumatology, Lennart Jacobsson, Sahlgrenska University, Gothenburg, Sweden.

**Lecturer:** Professor Glenn Haugeberg, Trondheim University, Norway  
**Time:** Thursday September 15th 2022 at 08:15-09:00 CET  
**Venue:** Eriksbergshallen, Gothenburg

### Agenda:

<b>08:15-08.15</b>	Welcome	Thomas Mandl, Medical Lead
<b>08:15-08:50</b>	Advances in the treatment of psoriatic arthritis	Glenn Haugeberg
<b>08:50-09:00</b>	Questions and answers	Glenn Haugeberg and Lennart Jacobsson

- Breakfast will be served in connection with the symposium
- Participation in the meeting requires approval from the head of department.
- Participation in the meeting is free of costs.

Welcome!  
Thomas Mandl  
Medical Lead Rheumatology  
Novartis Sweden AB

SE2209120182